First use of ibrutinib for the treatment of post-transplant central nervous system graft-versus-host disease
Br J Haematol
.
2023 Sep;202(5):1061-1064.
doi: 10.1111/bjh.18959.
Epub 2023 Jun 26.
Authors
Aaron Trando
1
,
Anastasie Dunn-Pirio
2
,
Divya Koura
3
,
Aaron M Goodman
3
Affiliations
1
University of California San Diego School of Medicine, San Diego, California, USA.
2
Department of Neurosciences, University of California San Diego, San Diego, California, USA.
3
Department of Medicine, Division of Blood and Marrow Transplantation, University of California San Diego, San Diego, California, USA.
PMID:
37357559
DOI:
10.1111/bjh.18959
No abstract available
Publication types
Letter
MeSH terms
Adenine
Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / etiology
Hematopoietic Stem Cell Transplantation*
Humans
Piperidines
Substances
ibrutinib
Piperidines
Adenine